After a decades-long hiatus, research on psychedelics as a treatment for psychiatric diseases is experiencing a renaissance—and initial results look promising.
In the newest episode of the BioRevolution podcast, Andreas Horchler and Louise von Stechow discuss the history, the promise, and the risks of psychedelics as treatments for psychiatric diseases with neuroscientist, psychedelics expert, and executive coach Galyna Pidpruzhnykova
The value of facts and evidence-based science seems to be increasingly questioned by those in power and by those in control of assets. If those who make laws and regulate science don’t see evidence and consensus as reliable resources anymore, what will become of progress in biomedicine, which feeds innovation in biotech, pharma, and medicine?
In episode 31 of the BioRevolution podcast, Andreas Horchler and Louise von Stechow explore various use cases for AI in biotech—from discovery to clinical development, from chemistry to biology, and from data-centric to algorithm-centric AI strategies—trying to assess where the biggest payoff will be.
In episode 30 of the biorevolution podcast Andreas Horchler and Louise von Stechow talk about the human need for self-improvement. We discuss how modern biohacking practices, from diet regimens, to cold exposure, to supplements and DIY cognitive behavioral therapy, dopamine fasting and cortisol detox are entering the mainstream via social media influencers and podcasts and which of those are actually useful for feeling better about ourselves.
In episode 29 of the biorevolution podcast Andreas Horchler and Louise von Stechow talk about the science of stress and so-called cortisol detox practices. Cortisol is an important stress hormone that regulates many physiological and pathological processes. Chronic deregulation of cortisol can lead to disease. However, while modern humans are indeed very stressed, cortisol detox practices aren’t necessary and might induce more stress than they relieve.
In episode 31 of the BioRevolution podcast, Andreas Horchler and Louise von Stechow explore various use cases for AI in biotech—from discovery to clinical development, from chemistry to biology, and from data-centric to algorithm-centric AI strategies—trying to assess where the biggest payoff will be.
